NAD+
Nicotinamide adenine dinucleotide · NAD
Central redox coenzyme; declines with age (mechanistic interest)
Overview
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme present in every cell, where it shuttles electrons in redox reactions central to energy metabolism and serves as a substrate for enzymes such as sirtuins and PARPs. Tissue NAD+ levels are reported to decline with age, which underpins much of the interest in restoring NAD+ within healthy-aging research.
Most rigorous human evidence concerns oral NAD+ precursors (such as nicotinamide riboside and nicotinamide mononucleotide), which raise NAD+ metabolites in blood. Direct injectable NAD+ is widely used in wellness and clinic settings and is frequently administered intravenously, often as a slow infusion because rapid administration is commonly reported to cause transient discomfort (flushing, chest tightness, nausea). Subcutaneous administration is also used in community protocols.
Because injectable NAD+ is typically a compounded or research preparation rather than an approved drug, and because controlled longevity outcomes in humans are not established, the dose ranges below are illustrative of community and clinic practice and should be verified. NAD+ doses are large relative to most peptides — measured in tens to hundreds of milligrams — and the worked reconstitutions reflect this.
Key parameters
- Dose range
- Wide range by route, e.g. 50–500 mg (community/clinic)
- Frequency
- Daily to weekly
- Half-life
- Short (intact NAD+ is rapidly metabolized in circulation)
- Route
- IV (also subcutaneous)
- Vial sizes
- 100 mg · 500 mg · 750 mg
- Regulatory status
- Endogenous coenzyme; injectable forms compounded/research.
Mechanism of action
Redox electron transfer (NAD+/NADH)
Acts as the principal electron carrier in glycolysis, the citric-acid cycle, and oxidative phosphorylation, making it central to cellular energy production.
Sirtuin co-substrate
Serves as a required substrate for sirtuin enzymes implicated in stress resistance and metabolic regulation; sirtuin activity depends on available NAD+.
PARP / DNA-repair signaling
Consumed by poly(ADP-ribose) polymerases during DNA-damage responses, linking NAD+ availability to genome maintenance.
Dosing protocol & phases
| Phase | Weeks | Dose | Notes |
|---|---|---|---|
| Lower (subcutaneous, community) | Ongoing | ~50–100 mg per administration | Smaller subcutaneous doses are often used to limit discomfort; community-derived. |
| Higher (IV infusion, clinic) | Periodic | ~250–500 mg (or more) by slow IV | Frequently given as a slow intravenous infusion over an hour or more; rapid administration is poorly tolerated. |
Reconstitution guide
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
500 mg vial + 5 mL bacteriostatic water
Concentration100,000 mcg/mL · 100 mg/mL
| Target dose | Draw volume | U-100 units |
|---|---|---|
| 50,000 mcg | 0.5 mL | 50 |
| 100,000 mcg | 1 mL | 100 |
| 250,000 mcg | 2.5 mL | 250 |
| 500,000 mcg | 5 mL | 500 |
Higher-fill vial suited to larger doses; NAD+ is frequently diluted further into IV fluid for slow infusion.
100 mg vial + 2 mL bacteriostatic water
Concentration50,000 mcg/mL · 50 mg/mL
| Target dose | Draw volume | U-100 units |
|---|---|---|
| 50,000 mcg | 1 mL | 100 |
| 100,000 mcg | 2 mL | 200 |
Smaller vial for lower subcutaneous doses.
Reconstitution calculator
Pre-filled with NAD+'s vial sizes. Adjust the water volume and target dose to see the exact draw, with warnings for doses that are hard to measure or won't fit a syringe.
At 20,000 micrograms per millilitre, a 50,000 microgram dose is 2.5 millilitres, or 250 units on a U-100 syringe, giving 2 doses per vial.
This draw is 250 units, which won't fit in a 50-unit syringe. Use more bacteriostatic water (lower concentration) or split the dose.
Supplies needed
Affiliate disclosure: we may earn a commission from supplier links, at no extra cost to you. For research and educational use only.
Recommended supply
NAD+ — research vial
From our verified partner Dynotides, with a third-party certificate of analysis per batch.
Injection supplies
- View
Bacteriostatic water
Diluent for reconstituting lyophilized vials.
- Buy
Insulin syringes (U-100)
0.3–0.5 mL, 29–31 G for accurate small draws.
- Buy
Alcohol prep pads
Sterile swabs for the vial stopper and site.
- Buy
Sharps container
Safe disposal of used needles.
- Buy
Storage fridge
Keeps reconstituted vials at 2–8 °C.
- Buy
Insulated travel case
Cooled, TSA-friendly case for travel.
Missed-dose guidance
No approved-label guidance exists for injectable NAD+. As an endogenous coenzyme used on flexible community/clinic schedules, a missed administration is generally resumed at the next planned session rather than doubled.
Side effects & safety
| Category | Effect | Trial incidence |
|---|---|---|
| Infusion-related | Flushing, chest tightness, nausea with rapid IVCommonly reported when infused too quickly; mitigated by slowing the infusion. | — |
| Injection site | Local discomfort (subcutaneous) | — |
| General | Lightheadedness / crampingAnecdotal; controlled incidence data for injectable NAD+ are limited. | — |
Clinical trials & evidence
NAD+ precursor trials (NR / NMN)
Phase 1/2Varies · Adults (various)
Oral precursors reliably raise blood NAD+ metabolites and are generally well tolerated in short-to-medium-term trials; clinical longevity endpoints are not established.
Trial identifier needs verification
Injectable NAD+ controlled trials
Not well establishedN/A · N/A
Rigorous controlled trials of injectable NAD+ for longevity outcomes are lacking; most human evidence concerns the oral precursors rather than direct NAD+ injection.
Trial identifier needs verification
Storage & handling
- Lyophilized
- Refrigerate lyophilized powder at 2–8 °C, protected from light; NAD+ is sensitive to heat and moisture.
- Reconstituted
- Refrigerate at 2–8 °C and use promptly (NAD+ in solution degrades); do not freeze. Confirm the stability window with the preparing pharmacy.
Comparisons
| Vs. | Target | Half-life | Dosing | Efficacy | Status |
|---|---|---|---|---|---|
| MOTS-c | Redox coenzyme vs mitochondrial peptide | Short vs not characterized | Tens–hundreds of mg, often IV vs mg subcutaneous | Different mechanisms within mitochondrial/metabolic biology | Both not approved as drugs |
| Glutathione | Coenzyme/redox cofactor vs antioxidant tripeptide | Short (both) | Often IV (both in clinic settings) | Complementary antioxidant/metabolic rationale; sometimes co-administered | Both compounded/research for injectable use |
Sources & references
Frequently asked questions
Why is injectable NAD+ often given intravenously and slowly?
Rapid administration of NAD+ is commonly associated with transient flushing, chest tightness, and nausea. Slowing the infusion is the usual way to improve tolerability, which is why clinic protocols frequently use a slow IV drip.
Is injectable NAD+ proven to extend lifespan?
No. NAD+ biology is an active area of healthy-aging research, and oral precursors reliably raise NAD+ metabolites, but controlled human trials demonstrating longevity benefits from injectable NAD+ are not established. The figures here are illustrative of community/clinic practice rather than label-driven.
Related protocols
MOTS-c
Mitochondrial-derived peptide
Mitochondrial-derived peptide regulating metabolic homeostasis (preclinical)
SS-31
Elamipretide
40 mg/day SC; MMPOWER-3 Phase 3 missed its 6-minute-walk primary endpoint
Glutathione
GSH
Oral 500 mg/day reduced the melanin index vs placebo in RCTs; IV use for skin lightening is not recommended
Looking to match this protocol to a verified research vial? Our partner supplier publishes a certificate of analysis per batch.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.